

Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Polish innovative drug for the treatment of diabetes type II based on a mechanism of interaction through PPAR receptors – preclinical study	Sectoral Operational Programme Increase of Economic Competitiveness 2004-2006, Priority 1. Development of entrepreneurship and innovation by strengthening business environment institutions. Measure 1.4. Strengthening co-operation between science and industry.	Adamed Sp. z o.o.	17 052 067,78	7 526 888,47	01.02.2006 30.11.2008

Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Development of Polish innovative drug for the treatment of central nervous system diseases: schizophrenia, depression and anxiety – preclinical study	I Technological Initiative	Adamed Sp. z o.o.	27 800 889,00	16 402 520,00	01.05.2008 30.04.2013



Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
3CLA - biotechnology, targeted anti-cancer drug	Innovative Economy Operational Programme 2007-2013. Priority 1. Research and development of new technologies Measure 1.4. Support for targeted projects	Adamed Sp. z o.o.	54 354 582,14	27 177 118,67	22.10.2008 31.12.2015
Development and implementation of a package of new generation cardiac drugs	Innovative Economy Operational Programme 2007-2013 under Measure 1.4 Support for special projects Priority Axis 1. Research and development of new technologies and Measure 4.1. Support for implementation of results of R & D Priority Axis 4. Investments in innovative undertakings	Adamed Sp. z o.o.	6 013 000,00	1 503 250,00	01.12.2009 30.06.2014
New complex drugs for the treatment of cardiovascular system diseases	Innovative Economy Operational Programme 2007-2013. Priority 1. Research and development of new technologies, Measure 1.4. Support for targeted projects	Adamed Sp. z o.o.	7 770 731,19	3 694 380,00	07.05.2012 31.12.2015
An inhalation medicine of the latest generation for the treatment of respiratory diseases	Innovative Economy Operational Programme 2007-2013. Priority 1. Research and development of new technologies, Measure 1.4. Support for targeted projects	Adamed Pharma S.A.	14 704 150,77	7 279 880,00	01.06.2012 31.12.2015

Development and validation of a technology of a complex drug forms in real conditions	Innovative Economy Operational Programme 2007-2013. Measure 1.5 "System project of the National Centre for Research and Development". Project pilot "DEMONSTRATOR + Supporting scientific research and development works in demonstration scale"	Adamed Sp. z o.o.	5 480 100,00	1 370 025,00	01.05.2013 30.11.2015
Development and implementation of novel antidyslipidemics	Innovative Economy Operational Programme 2007-2013. Measure 1.5 Sectoral programme INNOMED	Adamed Sp. z o.o.	12 269 400,00	3 096 804,00	10.07.2013 30.09.2017
Next generation anticancer bioconjugates	Innovative Economy Operational Programme 2007-2013. Measure 1.5 Sectoral programme INNOMED	Adamed Sp. z o.o.	19 942 700 ,00	9 971 350,00	01.03.2014 28.02.2019



Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Development of new protein carriers technologies for use in anti-cancer therapies	„INNOTECH” programme. In-Tech programme path	Adamed Sp. z o.o.	6 280 188,00	3 705 311,00	01.04.2012 31.03.2015



Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Preclinical and clinical development of anticancer therapy based on a new TRAIL-derived biomolecule focused on cell death signaling. Establishment of a national center for early phase oncological clinical studies.	STRATEGMED programme "Prevention and treatment of civilization diseases" – 2 nd edition	Consortium: Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology; and Adamed Sp. z o.o.	21 550 490,00	18 487 740,00 Grant for Adamed Sp. z o.o. 5 637 875,00	01.09.2015 31.08.2018
Mesenchymal stromal cells enriching scaffolds as an alternative form of therapy for patients with heart failure.	STRATEGMED programme "Prevention and treatment of civilization diseases" -2 nd edition	Consortium: Silesian Center for Heart Diseases; and Adamed Sp. z o.o.	15 469 700,00	14 216 305,00 Grant for Adamed Sp. z o.o. 650 930,00	01.07.2015 30.06.2019



Project title	Project goal and planned effects	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Preclinical development of novel anticancer drug based on p53 protein reactivation – Acronym: ONCO-p53	<p>The aim of the project is to conduct pre-clinical studies on a candidate for a new targeted anticancer drug.</p> <p>The effect of the project will be a developed candidate for a targeted anti-cancer drug with therapeutic properties tested in in-vivo conditions, including efficacy and safety of use.</p>	INNOMED Programme Edition 2/1.2/2015_INNOMED"	Adamed Sp. z o.o.	17 872 355,17	9 999 811,38	01.01.2016 31.12.2019
Enlargement and provision of equipment for the Research and Development Centre of Pharmaceutical Plant Polfa S.A. in Pabianice	<p>The aim of the project is to establish an organizational unit dedicated to conducting R & D activities in the field of a pilot production of drug candidates developed by the Adamed Group.</p> <p>The effect of the project will be infrastructure facilities required for the implementation of innovative R & D projects, included in the Research Agenda, as well as conducted in the following years. As a result of their successful completion, patients will receive wide access to high quality and competitively priced medicinal products with the desired efficacy and safety profile.</p>	Smart Growth Operational Programme 2014-2020. Measure 2.1 "Support for investment in infrastructure, R & D enterprises"	Pabianickie Zakłady Farmaceutyczne Polfa S.A.	29 531 962,50	8 268 949,50	17.11.2015 31.12.2017
Development of an innovative urological drug with Furazidine, as a response to growing drug-resistance of microorganisms that cause urinary tract infections (UTI).	<p>The aim of the project is to develop an innovative form of modified-release Furazidine (MR), used in the treatment of acute and recurrent urinary tract infection.</p> <p>The effect of the project will be a modified drug with a sustainable release that will provide patients with effective, safe and convenient UTI therapy - a modified release profile will reduce the number of necessary tablets to one per day.</p>	Smart Growth Operational Programme 2014-2020. Measure 1.1 "Projects R & D Enterprises", Sub-measure 1.1.1 "Industrial research and development work carried out by undertakings"	Pabianickie Zakłady Farmaceutyczne Polfa S.A.	18 788 507,84	7 861 187,23	01.06.2016 31.01.2022
The development of innovative dermatological compositions for use in the course of radiotherapy	<p>The aim of the project is to develop 4 preparations in the form of clinically tested medical devices for use on the irradiated skin as a result of oncological procedures, the effect of which are "radiation reactions" of normal tissues, appearing on the skin as early as in the first week of therapy.</p> <p>The project will result in new preventive and therapeutic medical devices that will be directed to people with dermatological problems arising after the use of radiotherapy.</p>	Smart Growth Operational Programme 2014-2020. Measure 4.1 "Research and development", Sub-measure 4.1.2 "Regional Agenda for Research"	Consortium: Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology; and Pabianickie Zakłady Farmaceutyczne Polfa S.A.	3 083 609,44	2 060 705,81 Grant for PZF Polfa S.A. 1 162 262,81	01.08.2016 31.01.2019
Development of drug candidates for the treatment of psychotic and cognitive disorders in dementia	<p>The aim of the project is to develop candidates for an innovative drug dedicated to the therapy of psychotic disorders in dementia, especially of the Alzheimer's type. The essential functionality of the result of the project will be the pharmacological activity of the new drug candidate, which outbalances the competitive therapies in terms of effectiveness and / or safety.</p> <p>The effect of the project will be a developed drug candidate for the treatment of psychotic disorders in dementia, especially of the Alzheimer's type, being a new chemical molecule with an efficacy and safety profile verified in clinical trials.</p>	Smart Growth Operational Programme 2014-2020. Measure 1.1 "Projects R & D Enterprises", Sub-measure 1.1.1 "Industrial research and development works carried out by undertakings"	Adamed Sp. z o.o.	55 502 648,21	25 796 383,65	01.06.2017 31.12.2023
Development of innovative drug for the treatment of vaginal infections	<p>The goal of the project is performing R & D studies aimed at developing a drug composition with furazidine and an antifungal substance with the desired absorption profile, effectiveness and safety of its use.</p> <p>The result of the project will be a complexed drug containing furazidine and an antifungal substance with an innovative therapeutic indication: bacterial and mixed vaginosis.</p>	Smart Growth Operational Programme 2014-2020. Measure 1.1 "Projects R & D Enterprises", Sub-measure 1.1.1 "Industrial research and development works carried out by undertakings"	Adamed Sp. z o.o.	47 398 949,60	21 721 780,59	01.12.2017 31.12.2023